Bio-Rad Laboratories (FRA:BUWA) Total Receivables: €369 Mil (As of Mar. 2026)


FRA:BUWA Bio-Rad Laboratories Inc FRA:BUWA
72 GF Score
Price €257.40
GF Value €275.94
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Bio-Rad Laboratories Total Receivables?

Bio-Rad Laboratories FRA:BUWA -0.08% 72 Total Receivables is €369 Mil as of Mar. 2026. GuruFocus rates FRA:BUWA with a GF Score™ of 72/100 and a GF Value™ of €275.94 (Fairly Valued). The stock has 5 warning signs investors should review.

Bio-Rad Laboratories's Total Receivables for the quarter that ended in Mar. 2026 was €369 Mil.

Bio-Rad Laboratories Total Receivables Related Terms

Bio-Rad Laboratories Total Receivables Historical Data

* Premium members only.

The historical data trend for Bio-Rad Laboratories's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Rad Laboratories Total Receivables Chart

Bio-Rad Laboratories Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 374.83 466.95 448.41 432.14 393.35

Bio-Rad Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 392.85 407.40 395.92 393.35 368.66
FRA:BUWA
72GF Score
Bio-Rad Laboratories Inc FRA:BUWA
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bio-Rad Laboratories Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €369 Mil mean?
Bio-Rad Laboratories (FRA:BUWA) has a Total Receivables of €369 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Bio-Rad Laboratories and its competitors.
Is Bio-Rad Laboratories' Total Receivables too high?
Bio-Rad Laboratories' current Total Receivables is €369 Mil. Overall, Bio-Rad Laboratories has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bio-Rad Laboratories' Total Receivables compare to GKOS and BRKR?
Bio-Rad Laboratories' Total Receivables of €369 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Devices & Instruments company?
A good Total Receivables depends on the Medical Devices & Instruments industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Bio-Rad Laboratories and its competitors. Bio-Rad Laboratories's current Total Receivables is €369 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Rad Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Bio-Rad Laboratories (FRA:BUWA) is currently considered Fairly Valued. The stock's GF Value™ is €275.94, compared to a current price of €257.40 — trading 6.7% below its estimated fair value. The current Total Receivables is €369 Mil. Bio-Rad Laboratories' overall GF Score™ is 72/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Bio-Rad Laboratories (FRA:BUWA), the current Total Receivables is €369 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Rad Laboratories (FRA:BUWA) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Rad Laboratories stock appears to be undervalued. The current stock price of €257.40 is trading 6.7% below its estimated GF Value™ of €275.94. GuruFocus considers Bio-Rad Laboratories to be Fairly Valued.

Key valuation signals for FRA:BUWA:

  • Total Receivables: €369 Mil
  • GF Value™: €275.94 vs. price of €257.40 (6.7% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the FRA:BUWA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Rad Laboratories Business Description

Address 1000 Alfred Nobel Drive, Hercules, CA, USA, 94547
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
72GF Score

Get the complete analysis for FRA:BUWA

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€257.40
Price
€275.94
GF Value